Swedish biopharmaceutical company Calliditas Therapeutics signed and fully drew on a term loan of €92 million ($102.3 million) with funds managed by Athyrium Capital Management.
Funds managed by Athyrium Capital Management served as administrative agent on a $125 million expanded credit facility for Recro Pharma, a specialty pharmaceutical company focused on therapeutics for hospitals and other acute care settings.
Certain funds managed by Athyrium Capital Management and Highbridge Capital Management provided a facility consisting of $50 million in new secured first lien term loans and $22.5 million of new secured term loans to Novelion Therapeutics, a biopharmaceutical company.
Kala Pharmaceuticals closed a $110 million credit facility with funds managed by Athyrium Capital Management. Morgan Stanley acted as sole structuring agent on the transaction.
Recro Pharma secured a $100 million credit facility from funds managed by Athyrium Capital Management, a healthcare-focused investment firm.
Halozyme Therapeutics closed a $150 million royalty-backed debt transacton with investment funds managed by Pharmakon Advisors and Athyrium Capital Management.
InnoPharma announced that it closed on a $20 million term loan facility, provided by Athyrium Capital Management through the Athyrium Opportunities Fund.